A unique nanoparticulate TLR9 agonist enables a HA split vaccine to confer FcγR-mediated protection against heterologous lethal influenza virus infection.
Yamamoto T, Masuta Y, Momota M, Kanekiyo M, Kanuma T, Takahama S, Moriishi E, Yasutomi Y, Saito T, Graham BS, et al. Int Immunol. 2019 Feb 15; 31(2):81-90.